NurExone Biologic Recognized as a 2025 TSX Venture 50(TM) Top Performing Stock
NurExone Biologic has been named to the prestigious 2025 TSX Venture 50™, standing out as the only biotech company among three life sciences firms selected. The company achieved remarkable performance metrics, including 110% share price appreciation and 209% market cap growth.
The TSX Venture 50™ recognition, which evaluates companies based on share price appreciation and market capitalization growth, selected NurExone from 1,605 listed issuers. The company's success is driven by significant progress in developing ExoPTEN, their proprietary exosome therapy for acute spinal cord injuries, and the establishment of their U.S. subsidiary, Exo-Top Inc., which enhances their exosome production capabilities.
The 2025 TSX Venture 50™ companies demonstrated an impressive average share price appreciation of 207%, with 80% of the selected companies operating internationally across Europe, South America, Africa, and beyond.
NurExone Biologic è stata nominata tra le prestigiose 2025 TSX Venture 50™, distinguendosi come l'unica azienda biotecnologica tra le tre selezionate nel settore delle scienze della vita. L'azienda ha raggiunto metriche di prestazione straordinarie, tra cui un apprezzamento del 110% del prezzo delle azioni e una crescita del 209% della capitalizzazione di mercato.
Il riconoscimento della TSX Venture 50™, che valuta le aziende in base all'apprezzamento del prezzo delle azioni e alla crescita della capitalizzazione di mercato, ha selezionato NurExone tra 1.605 emittenti quotati. Il successo dell'azienda è guidato da progressi significativi nello sviluppo di ExoPTEN, la loro terapia a base di esosomi per le lesioni acute del midollo spinale, e dalla creazione della loro filiale negli Stati Uniti, Exo-Top Inc., che migliora le loro capacità di produzione di esosomi.
Le aziende della TSX Venture 50™ del 2025 hanno dimostrato un impressionante apprezzamento medio del prezzo delle azioni del 207%, con l'80% delle aziende selezionate che operano a livello internazionale in Europa, Sud America, Africa e oltre.
NurExone Biologic ha sido nombrada en el prestigioso 2025 TSX Venture 50™, destacándose como la única empresa biotecnológica entre las tres firmas de ciencias de la vida seleccionadas. La compañía logró métricas de rendimiento notables, incluyendo un 110% de apreciación en el precio de las acciones y un 209% de crecimiento en la capitalización de mercado.
El reconocimiento de TSX Venture 50™, que evalúa a las empresas en función de la apreciación del precio de las acciones y el crecimiento de la capitalización de mercado, seleccionó a NurExone de entre 1,605 emisores listados. El éxito de la empresa se debe a un progreso significativo en el desarrollo de ExoPTEN, su terapia de exosomas patentada para lesiones agudas de la médula espinal, y al establecimiento de su filial en EE. UU., Exo-Top Inc., que mejora sus capacidades de producción de exosomas.
Las empresas del TSX Venture 50™ de 2025 demostraron una impresionante apreciación promedio del precio de las acciones del 207%, con el 80% de las empresas seleccionadas operando internacionalmente en Europa, Sudamérica, África y más allá.
NurExone Biologic는 명망 있는 2025 TSX Venture 50™에 이름을 올렸으며, 선정된 세 개의 생명 과학 기업 중 유일한 생명공학 회사로 두드러집니다. 이 회사는 주가 110% 상승 및 시가 총액 209% 성장을 포함한 놀라운 성과 지표를 달성했습니다.
주가 상승 및 시가 총액 성장에 따라 기업을 평가하는 TSX Venture 50™의 인정을 받은 NurExone은 1,605개의 상장 기업 중에서 선정되었습니다. 이 회사의 성공은 급성 척수 손상을 위한 독점적인 엑소좀 치료제인 ExoPTEN 개발에서의 중요한 진전을 통해 이루어졌으며, 엑소좀 생산 능력을 향상시키는 미국 자회사 Exo-Top Inc.의 설립에 기인합니다.
2025 TSX Venture 50™ 기업들은 평균 207%의 주가 상승률을 기록했으며, 선정된 기업의 80%가 유럽, 남미, 아프리카 등에서 국제적으로 운영되고 있습니다.
NurExone Biologic a été nommée dans le prestigieux 2025 TSX Venture 50™, se distinguant comme la seule entreprise biotechnologique parmi les trois sociétés de sciences de la vie sélectionnées. L'entreprise a atteint des indicateurs de performance remarquables, y compris une appréciation de 110% du prix de l'action et une croissance de 209% de la capitalisation boursière.
La reconnaissance du TSX Venture 50™, qui évalue les entreprises en fonction de l'appréciation du prix des actions et de la croissance de la capitalisation boursière, a sélectionné NurExone parmi 1 605 émetteurs cotés. Le succès de l'entreprise est soutenu par des progrès significatifs dans le développement de ExoPTEN, leur thérapie par exosomes pour les blessures aiguës de la moelle épinière, et l'établissement de leur filiale américaine, Exo-Top Inc., qui améliore leurs capacités de production d'exosomes.
Les entreprises du TSX Venture 50™ de 2025 ont affiché une appréciation moyenne impressionnante du prix des actions de 207%, avec 80% des entreprises sélectionnées opérant à l'international en Europe, en Amérique du Sud, en Afrique et au-delà.
NurExone Biologic wurde in die prestigeträchtigen 2025 TSX Venture 50™ aufgenommen und hebt sich als das einzige Biotechnologieunternehmen unter den drei ausgewählten Unternehmen im Bereich Lebenswissenschaften hervor. Das Unternehmen erzielte bemerkenswerte Leistungskennzahlen, darunter eine 110%ige Wertsteigerung der Aktien und ein 209%iges Wachstum der Marktkapitalisierung.
Die Auszeichnung der TSX Venture 50™, die Unternehmen auf der Grundlage der Wertsteigerung des Aktienkurses und des Wachstums der Marktkapitalisierung bewertet, wählte NurExone aus 1.605 gelisteten Emittenten aus. Der Erfolg des Unternehmens wird durch bedeutende Fortschritte bei der Entwicklung von ExoPTEN, ihrer proprietären Exosomtherapie für akute Rückenmarksverletzungen, und der Gründung ihrer US-Tochtergesellschaft Exo-Top Inc. vorangetrieben, die ihre Exosomproduktionskapazitäten verbessert.
Die Unternehmen der TSX Venture 50™ von 2025 zeigten eine beeindruckende durchschnittliche Wertsteigerung des Aktienkurses von 207%, wobei 80% der ausgewählten Unternehmen international in Europa, Südamerika, Afrika und darüber hinaus tätig sind.
- None.
- None.
Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - March 10, 2025) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company") is proud to announce its inclusion in the 2025 TSX Venture 50™, a prestigious annual ranking of the top-performing companies on the TSX Venture Exchange ("TSXV"). NurExone is honored to be the only biotech company, and one of three life sciences companies, to receive this designation, highlighting NurExone's leadership in the emerging field of exosome-based therapies and regenerative medicine for central nervous system injuries. This recognition also highlights NurExone's strong market performance and strategic advances in the past year including
The TSX Venture 50™ recognizes the top 50 performing issuers out of the 1,605i listed issuers on the TSXV, across all sectors. Each company recognized is evaluated and chosen based on a combination of metrics including one year share price appreciation and market capitalization growth. In 2024, the 50 selected companies delivered an impressive average share price appreciation of
"We are deeply honored to be recognized as a TSX Venture 50™ company. This reflects our unwavering commitment to advancing exosome-based therapies and creating long-term value for our shareholders," said Dr. Lior Shaltiel, CEO of NurExone. "It's a testament to the growing investor confidence in our mission to revolutionize regenerative medicine, the strength of our scientific breakthroughs, and the dedication of our talented team."
Key milestones driving NurExone's success include significant progress in the development of ExoPTEN, the Company's proprietary exosome therapy for acute spinal cord injuries, as well as NurExone's establishment of its U.S. subsidiary, Exo-Top Inc., which accelerates its exosome production capabilities and advancement of their clinical pipeline. These efforts will help position NurExone as a leader in the rapidly growing field of exosome-based therapies.
The TSXV serves as a vital platform for early-stage, high-growth companies, providing access to capital and a strong investor network. In 2024,
Yoram Drucker, Chairman of NurExone, added "being recognized by the TSX Venture 50™ is a significant milestone for NurExone, highlighting our strong financial performance and growth trajectory. We look forward to continuing our success as we expand our presence in the U.S. and explore new listing opportunities."
About NurExone
NurExone Biologic Inc. is a TSXV, OTCQB and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar markets[iv]. Regulatory milestones, including Orphan Drug Designation, facilitate the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.
For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Oak Hill Financial Inc.
2 Bloor Street, Suite 2900
Toronto, Ontario M4W 3E2
Investor Relations - Canada
Phone: +1-647-479-5803
Email: info@oakhillfinancial.ca
Dr. Eva Reuter
Investor Relations - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
Allele Capital Partners
Investor Relations - U.S.
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com
FORWARD-LOOKING STATEMENTS
This press release contains certain "forward-looking statements" that reflect the Company's current expectations and projections about its future results. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the Company's advancing exosome-based therapies and creating long term value for shareholders; growing investor confidence in the Company's mission; Exo-Top Inc. accelerating its exosome production capabilities and advancing its clinical pipeline; the Company becoming a leader in the field of exosome-based therapies; the continued success of the Company; the Company expanding its presence in the U.S. and exploring new listing opportunities; the Company completing clinical trials in the U.S. and Europe; the Company's future plans and expectations; growing clinical demand for innovative treatments in spinal cord, optic nerve, and other therapeutic areas; NurExone advancing its development pipeline; NurExone's focus on developing regenerative exosome-based therapies for central nervous system injuries; and the NurExone platform technology offering solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications.
These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company will advance exosome-based therapies and create long term value for shareholders; there being growing investor confidence in the Company's mission; Exo-Top Inc. will accelerate its exosome production capabilities and advance its clinical pipeline; the Company will become a leader in the field of exosome-based therapies; the Company will continue to succeed; the Company will expand its presence in the U.S. and explore new listing opportunities; the Company will complete clinical trials in the U.S. and Europe; there will be growing clinical demand for innovative treatments in spinal cord, optic nerve, and other therapeutic areas; NurExone will advance its development pipeline; NurExone will continue to focus on developing regenerative exosome-based therapies for central nervous system injuries; and the NurExone platform technology will offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company's early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel, and on the Company's strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company's intellectual property and technology won't have the intended impact on the Company and/or its business; the Company's inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the inability of the Company to realize on the benefits of exosomes; the inability of the Company to produce and/or supply exosomes for a wide range of applications; the inability of the Company's products to be used for patient treatment; there not being broader adoption in the field and/or cell therapy applications; the inability of the Company to fulfill its intended future plans and expectations; the Company's inability to expand into further studies; Exo-Top not have the intended benefits on the Company and/or its business; the Company be unable to advance exosome-based therapies and/or create long term value for shareholders; investor confidence in the Company's mission deteriorating; the Company not becoming a leader in the field of exosome-based therapies; the Company being unable to expand its presence in the U.S. and/or explore new listing opportunities; the Company being unable to initiate and/or complete clinical trials in the U.S. and Europe; clinical demand for innovative treatments in spinal cord, optic nerve, and other therapeutic areas deteriorating; NurExone being unable to advance its development pipeline; NurExone being unable to focus on developing regenerative exosome-based therapies for central nervous system injuries; the NurExone platform technology being unable to offer solutions to companies interested in quality exosomes and/or minimally invasive targeted delivery systems for other indications; and the risks discussed under the heading "Risk Factors" on pages 44 to 51 of the Company's annual information form dated August 27, 2024, a copy of which is available under the Company's SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
i TMX
ii https://money.tmx.com/en/venture50
iii https://money.tmx.com/en/venture50
iv Spinal cord injury, Glaucoma
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/241616
FAQ
What performance metrics earned NurExone (NRXBF) a spot in the 2025 TSX Venture 50?
How many companies did NurExone (NRXBF) compete against for the TSX Venture 50 recognition?
What is ExoPTEN and how does it relate to NurExone's (NRXBF) success?
How does NurExone's (NRXBF) U.S. subsidiary Exo-Top Inc. contribute to its growth?
What distinguishes NurExone (NRXBF) among other TSX Venture 50 healthcare companies in 2025?
